financetom
Business
financetom
/
Business
/
Tata, GIC-led investor group buying stake in GMR Airports for Rs 8,000 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata, GIC-led investor group buying stake in GMR Airports for Rs 8,000 crore
Mar 26, 2019 11:51 PM

GMR Infrastructure Ltd said Tata Group, Singapore’s sovereign wealth fund GIC Pvt Ltd and private equity firm SSG Capital Management have agreed to invest Rs 8,000 crore in its airport unit.

Share Market Live

NSE

CNBC-TV18 first reported about the deal on March 26.

The investment in GMR Airports Ltd gives the infrastructure company a fillip in its mainstay business, which is facing stiff competition from new entrants such as the Adani Group.

GMR Infra said it has signed an agreement under which Tata and GIC will infuse Rs 1,000 crore in GMR Airports, and will purchase GMR Airports' shares from GMR Infra and subsidiaries for Rs 7,000 crore, according to the release.

As part of the deal, GMR Infra will retain management control over the airports business, with the Investors having customary rights and board representation at GMR Airports and its subsidiaries.

Following the completion of the acquisition, GMR Indra will hold 54 percent stake in GAL, Tata will own 20 percent stake, GIC will hold 15 percent stake and SSG will own 10 percent stake, said the company.

The deal "will reduce our debt substantially, strengthening our balance sheet," said Grandhi Kiran Kumar, managing director and CEO, GMR Infra.

GMR, which has a debt of over Rs 20,000 crore, has been making efforts to monetise its business to raise funds to repay debt and a large portion of the funds raised will be used for that purpose. The parent company GMR Infrastructure currently owns 92 percent of GMR Airport. GMR currently operates the airports in Delhi, Hyderabad and Cebu (the Philippines) among others.

First Published:Mar 27, 2019 7:51 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Astronics Q3 sales miss estimates
Astronics Q3 sales miss estimates
Nov 4, 2025
Overview * Astronics ( ATRO ) Q3 sales up 3.8% to $211.4 mln, missing analyst expectations * Company reports Q3 net loss of $11.1 mln due to refinancing-related charges * Adjusted EBITDA for Q3 was $32.7 mln, or 15.5% of sales Outlook * Company expects Q4 revenue between $225 mln and $235 mln * Astronics ( ATRO ) sees 2025...
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Nov 4, 2025
BOULDER, Colo. & NEW YORK--(BUSINESS WIRE)-- Infleqtion, a global leader in neutral-atom–based quantum technology, and Churchill Capital Corp X ( CCCX ) , a publicly traded special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on October 29, 2025. The submission...
Equitable Holdings Q3 EPS misses estimates
Equitable Holdings Q3 EPS misses estimates
Nov 4, 2025
Overview * Equitable Holdings ( EQH ) reports Q3 net loss of $1.3 bln due to life reinsurance impact * Adjusted EPS for Q3 misses analyst expectations * Assets under management rose 7% yr/yr to $1.1 trillion Outlook * Equitable Holdings ( EQH ) maintains confidence in achieving 2027 financial targets * Company plans $1.5 bln capital deployment for growth...
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Nov 4, 2025
Overview * Niagen Bioscience ( NAGE ) Q3 net sales rise 33%, beating analyst expectations * Adjusted EBITDA for Q3 increases 120%, reflecting improved operational performance * Company reaffirms full-year net sales growth outlook of 25% to 30% Outlook * Niagen Bioscience ( NAGE ) reaffirms 2025 net sales growth of 25% to 30% y-o-y * Company expects 2025 gross...
Copyright 2023-2026 - www.financetom.com All Rights Reserved